H.C. Wainwright Releases a Buy Rating on Tesaro

By Jason Carr

H.C. Wainwright analyst Edward White assigned a Buy rating to Tesaro (NASDAQ: TSRO) today and set a price target of $158. The company’s shares closed yesterday at $71.66, close to its 52-week low of $71.50.

According to TipRanks.com, White is a 5-star analyst with an average return of 22.4% and a 54.8% success rate. White covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Syndax Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Tesaro is Moderate Buy and the average price target is $136.47, representing a 90.4% upside.

In a report issued on January 3, Guggenheim also reiterated a Buy rating on the stock with a $125 price target.

The company has a one-year high of $192.94 and a one-year low of $71.50. Currently, Tesaro has an average volume of 892.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib. The company was founded by Leon Moulder, Jr., Mary Lynne Hedley, and Richard J.